Modulation of the human immune system to recognize tumor cells is the underlying principle behind cancer immunotherapy. Over the past several years drug manufacturers have seen amazing success with newly released immune-oncology therapies, many of which are centered around the programmed cell death ligand-1, or PD-L1 molecule. PD-L1, not only serves as a target for immunotherapy but also as a critical cancer biomarker—so high-quality detection reagents for this protein are imperative. In this podcast, GEN spoke with Rachel Gonzalez, Ph.D., a senior scientist at OriGene Technologies, about her continuing research on PD-L1 and the potential her work could have for improved cancer diagnostics and therapies.


Rachel Gonzalez, Ph.D.

Senior Scientist, Immunology

OriGene Technologies

This podcast is presented with support from:

Previous articleHow Fruit Flies Became our Bothersome Roommates
Next articleWrist-Worn Device Helps Link Physical Activity to 14 Genetic Loci